Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Aug 2015

Fiala Ondrej, Pesek Milos, Finek Jindrich, Minarik Marek, Benesova Lucie, Bortlicek Zbynek, Topolcan Ondrej

Abstract excerpt

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent novel effective agents approved for the treatment of patients with advanced-stage NSCLC. KRAS mutations have been reported as a negative prognostic and predictive factor in patients with NSCLC treated with EGFR-TKIs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins p21(ras)

Share to Quinazolines

Share to ras Proteins

Source

Identifiers

PMID: 25702091
DOI: 10.1007/s13277-015-3249-x

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25702091-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.PMID 25702091Read ↗

Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study.Semantic proximity Read ↗

KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.Semantic proximity Read ↗

KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials.Semantic proximity Read ↗

Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non-squamous non-small cell lung cancer patients.Semantic proximity Read ↗

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.Semantic proximity Read ↗

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?Semantic proximity Read ↗

Outcome of EGFR inhibitors treatment in advanced NSCLC patients, not enrolled in clinical trials.Semantic proximity Read ↗

A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

The role of statins as therapeutic agents in cancerSemantic proximity Read ↗

Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosisSemantic proximity Read ↗

The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.